Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (Allo-SCT)

Next Previous
X
Search
Trial Profile

Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (Allo-SCT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms VEN-DEC GITMO Study

    • Most Recent Events

    • 12 Dec 2023 Results of safety and efficacy data in final report presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Primary endpoint (Allo-SCT) has been met, as per results presented at the 28th Congress of the European Haematology Association.
    • 15 Jun 2023 Results (Data cut-off date February 18th, 2023) assessing the safety and efficacy of the chemo-free combination venetoclax plus decitabine as bridge to allo-SCT in elderly (greater than equal to 60 to less than 75 years) acute myeloid leukemia patients, presented at the 28th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top